BioMedNewsBreaks — GATC Health Corporation Releases Report on Recent Analysis Showing New Platform Performs 11x Better Than Industry Standard

GATC Health, a science and technology company revolutionizing drug discovery and disease prediction using its proprietary upgraded version 2.0 of its drug-discovery artificial intelligence (“AI”) platform, is reporting on its recently completed analysis. According to the release, the company’s upgraded drug-discovery platform forecasts drug-candidate success rate with 88% accuracy; the platform also predicts drug-failure rates with 84% accuracy. Biopharma companies can potentially save billions of dollars using the new offering, the company observed. The report provides further validation of the accuracy of GATC Health’s newly launched platform, which is designed to study and predict the biological success of drug compounds. The company just completed the extensive retrospective double-blinded analysis, which used machine-learning performance metrics to study real-world compounds and successfully predict drug success. The company noted that the new platform shows vast improvement in both speed and accuracy, with a proven 11 times increase over the current industry lead optimization success rate of approximately 8%. “Our groundbreaking platform has been validated to predict a potential drug’s safety and efficacy with a very high level of sensitivity and specificity,” said GATC Health chief marketing officer Preetaman Wadhwa in the press release. “The combination of speed, accuracy and GATC’s AI, which takes machine learning further than any of its known competitors in de-risking compounds even before entering human clinical trials, is expected to save billions in the future cost of drug development by accurately identifying which drug candidates are likely to succeed.”

To view the full press release, visit https://ibn.fm/EGjVy

About GATC Health Corporation

GATC Health is a pioneering technology company using whole genome analysis and multiomics-based artificial intelligence to revolutionize disease detection and drug discovery. The company’s patented AI platform reduces risk, time and costs for life science companies by digitally reproducing the human body to find nonobvious answers to biology’s most complex questions. GATC Health is accelerating healthcare’s transition to predictive, individualized medicine. For more information about the company, visit www.GATCHealth.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork